Jackson Center, PA, May 17, 2021 – Halberd Corporation (OTC-PINK: “HALB“) announces the successful conjugation of gold-coated iron nanoparticles with Halberd’s patent-pending monoclonal antibody against the SARS-CoV-2 spike protein.  This milestone paves the way for testing to proceed on the elimination of disease through the application of extracorporeal radio frequency waves or laser emissive energy to bodily fluids of infected patients.

Dr. Mitchell S. Felder, Halberd Corporation’s Chief Technical Officer stated, “Although we were successful earlier in conjugating solid gold nanoparticles with Halberd’s patent-pending monoclonal antibody, we found that the gold was not sufficiently reactive to the radiowaves to accomplish the efficient eradication of the disease antigen.  Iron oxide nanoparticles are the ideal metal for this process. Unfortunately, we were unable to create a stable conjugation of the iron oxide with our patent-pending antibody.  The gold-coated iron nanoparticle, by contrast, provides the combination of traits to satisfy both conditions:

  1. Sufficiently reactive to radio waves and laser emissive energy, and
  2. The ability to facilitate a stable conjugation.

Our patented extracorporeal approach to treatments is a necessary element to the eradication of disease through radiofrequency waves and laser emissive energy.”

William A. Hartman, Halberd’s Chairman, President & CEO, commented, “We commend the ingenuity and persistence of our team to seek a viable solution.  We now have a road to success with the appropriate combination of metallic properties for the disease eradication process. This discovery was only possible with the careful study and testing by Dr. Qiang Chen of GreenBioAZ.  With a suitable conjugation methodology achieved, we can now proceed with proof-of-concept testing at Youngstown State University (YSU) using E. coli as a first step.  After successful completion of testing at YSU, pathogenic virus testing at a secure Level 3 laboratory will be conducted under the direct supervision of Dr. Chen and the GreenBioAZ team, at the Arizona State University facility.”

To get the latest news on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
http://www.halberdcorporation.com
Twitter:@HalberdC

About Halberd Corporation.

Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  It holds the exclusive worldwide rights to several patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:

­­­Title Patent/
Application No.
Filing DateStatus/Document
*Method for Treating and Curing Covid-19 InfectionUS 62/98998103/16/2020Provisional
PCT/US21/2254103/16/2021International  PCT
*Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 PatientsUS 63/00720704/08/2020Provisional
Covid-19 Inflammatory Cytokine Storm TreatmentPCT/US21/2638604/08/2021International PCT
*Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the VirusUS 63/01310404/21/2020Provisional
Treating and Curing Covid-19 Infection Utilizing a LaserPCT/US21/2836804/21/2021International PCT
*Method For The Rapid Identification Of Covid-19 InfectionUS 63/04944107/08/2020Provisional
*Nasal Spray To Prevent The Transmission Of Covid-19 Between HumansUS 63/08073509/20/2020Provisional
*Nasal Spray To Prevent The Transmission Of The Covid-19 VirusUS 63/10830110/31/202Provisional
*Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The VirusUS 63/11104311/08/2020Provisional
*Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (Covid-19 Virus)US 63/13569501/10/2021Provisional

Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.